Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | ALDH1A2 | O94788 | 2/20 | 0.37 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7509246 | 0.86 | TSHR (0.46) | TSHRALDH1A1KDM4ESMN1; SMN2NPC1 | |
| SCHEMBL7503514 | 0.83 | TSHR (0.41) | TSHRALDH1A1KDM4ESMN1; SMN2NPC1 | |
| SCHEMBL7503519 | 0.76 | TSHR (0.45) | TSHRALDH1A1KDM4ESMN1; SMN2NPC1 | |
| SCHEMBL15033450 | 0.75 | TSHR (0.47) | TSHRALDH1A1KDM4ESMN1; SMN2NPC1 | |
| SCHEMBL9523406 | 0.75 | TSHR (0.44) | TSHRALDH1A1KDM4ESMN1; SMN2NPC1 | |
| SCHEMBL7449872 | 0.75 | TSHR (0.42) | TSHRALDH1A1KDM4ESMN1; SMN2NPC1 | |
| SCHEMBL9521448 | 0.74 | TSHR (0.46) | TSHRALDH1A1KDM4ESMN1; SMN2NPC1 | |
| SCHEMBL7513849 | 0.74 | ALDH1A1 (0.40) | ALDH1A1KDM4EHPGDGFERPDE10A | |
| SCHEMBL9876372 | 0.74 | TSHR (0.43) | TSHRALDH1A1KDM4ESMN1; SMN2NPC1 | |
| SCHEMBL9876370 | 0.74 | TSHR (0.43) | TSHRALDH1A1KDM4ESMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3318561-B1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2021-12-22 | — | — | EP | disclosed |
| US-10562916-B2 | Substituted quinoxalines as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| EP-2576540-B1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2019-09-04 | — | — | EP | disclosed |
| EP-3318561-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2018-05-09 | — | — | EP | disclosed |
| US-20180037590-A1 | SUBSTITUTED QUINOLINES AS PDE-10 INHIBITORS | SUNOVION PHARMACEUTICALS INC. | 2018-02-08 | — | — | US | disclosed |
| US-9834564-B2 | Substituted quinolines as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834564-B2 | Substituted quinolines as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20150166571-A1 | Heteroaryl Compounds and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. | 2015-06-18 | — | — | US | disclosed |
| US-8969349-B2 | Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20130158003-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2013-06-20 | — | — | US | disclosed |
| EP-2576540-A2 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| WO-2011150156-A2 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180037590-A1 | SUBSTITUTED QUINOLINES AS PDE-10 INHIBITORS | PDE10A, PDE2A, PDE3A | TSHR 2306/4885ALDH1A1 559/4885KDM4E 202/4885 |
| US-20130158003-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GPR119, NLN | TSHR 1653/4885ALDH1A1 560/4885KDM4E 969/4885 |
| US-10562916-B2 | Substituted quinoxalines as PDE-10 inhibitors | PDE4A, PDE2A, PDE9A | TSHR 2874/4885ALDH1A1 1140/4885KDM4E 1397/4885 |
| US-20150166571-A1 | Heteroaryl Compounds and Methods of Use Thereof | COMT, GPR119, NLN | TSHR 1653/4885ALDH1A1 560/4885KDM4E 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.